A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
Status:
Completed
Trial end date:
2021-04-26
Target enrollment:
Participant gender:
Summary
This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind,
placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male
and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and
selective antagonist of CCR4.